Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
Acta Urologica Belgica
|
March 1, 1997
Maximal androgen blockade versus total androgen suppression
H Dumez, H Van Poppel, L Baert, et al.
Acta Chirurgica Belgica
|
January 25, 2005
Surgical interventions during STI 571 treatment of metastatic GIST: experience in six patients
I Nevelsteen, I De Wever, M Stas, et al.
British Journal of Cancer
|
July 31, 2008
The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
P Wolter, C Stefan, B Decallonne, et al.
Cancer Chemotherapy and Pharmacology
|
April 6, 2011
Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies
P Schöffski, H Dumez, R Ruijter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 19, 2006
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review
P Schöffski, H Dumez, P Clement, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2010
A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
P Schöffski, P Reichardt, J-Y Blay, et al.
Investigational New Drugs
|
November 20, 2012
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
A H Awada, H Dumez, A Hendlisz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 29, 2011
Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
M J A de Jonge, H Dumez, J J E M Kitzen, et al.
Seminars in Oncology
|
June 8, 2001
Erythrocytes and the transfer of anticancer drugs and metabolites: a possible relationship with therapeutic outcome
H Dumez, M Highley, G Guetens, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 23, 2003
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours
F A L M Eskens, H Dumez, R Hoekstra, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
Acta Urologica Belgica
|
March 1, 1997
Maximal androgen blockade versus total androgen suppression
H Dumez, H Van Poppel, L Baert, et al.
Acta Chirurgica Belgica
|
January 25, 2005
Surgical interventions during STI 571 treatment of metastatic GIST: experience in six patients
I Nevelsteen, I De Wever, M Stas, et al.
British Journal of Cancer
|
July 31, 2008
The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
P Wolter, C Stefan, B Decallonne, et al.
Cancer Chemotherapy and Pharmacology
|
April 6, 2011
Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies
P Schöffski, H Dumez, R Ruijter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 19, 2006
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review
P Schöffski, H Dumez, P Clement, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2010
A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
P Schöffski, P Reichardt, J-Y Blay, et al.
Investigational New Drugs
|
November 20, 2012
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
A H Awada, H Dumez, A Hendlisz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 29, 2011
Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
M J A de Jonge, H Dumez, J J E M Kitzen, et al.
Seminars in Oncology
|
June 8, 2001
Erythrocytes and the transfer of anticancer drugs and metabolites: a possible relationship with therapeutic outcome
H Dumez, M Highley, G Guetens, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 23, 2003
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours
F A L M Eskens, H Dumez, R Hoekstra, et al.
Page
of 3